Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
Start Date
2/3/2019
Completion Date
4/1/2028
Summary
The primary objective of this study is to measure the concentration and the regional brain distribution of activated brain microglia/macrophages using the PET radiopharmaceutical \[F-18\]DPA-714 in individuals with chronic pain and fatigue suspected to be associated with neuroinflammation. The PET tracer \[F-18\]DPA-714 binds to the 18 kDa translocator protein (TSPO, also known as the peripheral benzodiazepine receptor) in the mitochondria of activated microglia/macrophages and provides a non-invasive measure of neuroinflammation. The primary objective of this study is to determine if pain and fatigue patients have higher levels of neuroinflammation than HC individuals as measured with \[F-18\]DPA-714-PET/MRI.
Eligibility Criteria
Age Range: 18 years to 65 years
Interventions
DPA-714 PET/MRI
Conditions
Locations
University of Alabama at Birmingham Medical Center
Birmingham, Alabama 35294
United States